Structural Studies of Ribonucleotide Reductase Complexes
核糖核苷酸还原酶复合物的结构研究
基本信息
- 批准号:8013604
- 负责人:
- 金额:$ 5.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAffinityAntineoplastic AgentsBindingBiological ModelsChemistryComplexCrystallizationDNA RepairDNA biosynthesisDataDeoxyribonucleotidesDiphosphatesDockingDrug Delivery SystemsDrug DesignEnzymesEquilibriumEscherichia coliFutureGasesHealthHumanIndividualLasersMethodsModelingMolecularMolecular Sieve ChromatographyMolecular WeightOrganismOxidoreductasePharmaceutical PreparationsPhaseProteinsRadialResolutionRibonucleotide ReductaseRibonucleotidesRoentgen RaysShapesSiteSolutionsStructureTimeX-Ray Crystallographyanticancer researchbasecancer therapydesigndimergemcitabineinhibitor/antagonistinsightlight scatteringmonomerprotein structurepublic health relevanceresponse
项目摘要
DESCRIPTION (provided by applicant): Ribonucleotide reductases (RNRs) are multi-subunit enzymes that are important targets for anti-cancer therapy and thus, directly relevant to human health. Intact complexes of class la RNRs, which include human and E. coli RNRs, have never been visualized by structural methods. Additionally, the oligomerization states of the inhibited class Ia RNR complexes are not well established, and it has been suggested that the inhibited RNRs may exist as higher order oligomers than the active complex. Incubation with the mechanism-based inhibitor and chemotherapeutic drug, gemcitabine (2',2'-difluoro-2'-deoxycytidine) diphosphate, has been shown to yield stable inhibited complexes of human and E. coli RNRs. Here, we propose a structural study of E. coli and human RNRs using X-ray crystallography and small-angle X-ray scattering (SAXS). Aim 1: To determine the quaternary structures of human and E. coli RNRs in solution using SAXS. The SAXS structures can be used to validate the docking model and future crystal structures of RNR complexes. The proposed solution SAXS studies will provide insight into how E. coli and human RNRs may form different oligomeric species in response to inhibitors and more significantly, how quaternary structure may regulate the overall activity of class la RNRs. Aim 2: To determine the crystal structure of human RNR inhibited by gemcitabine. Crystal structures of the gemcitabine-bound human RNR complex will allow us to identify how this drug may modify the active site and disrupt the catalytically essential radical transfer This structure will also allow us to observe the binding interactions between the subunits for the first time as well as provide insight into the future design of chemotherapeutic drugs that target this enzyme.
PUBLIC HEALTH RELEVANCE: Ribonucleotide reductase is a protein found in all organisms that is an important target for cancer drugs such as gemcitabine. Unlike many other proteins that are drug targets, however, the complete structure of this protein has never been solved. By studying the structure of this protein, we will understand more about cancer drugs that are currently in use and aid future drug design efforts.
描述(由申请人提供):核糖核苷酸还原酶(RNR)是多亚基酶,是抗癌治疗的重要靶标,因此与人类健康直接相关。完整的la类RNR复合物,包括人和E.大肠杆菌RNR,从来没有被可视化的结构方法。此外,受抑制的Ia类RNR复合物的寡聚化状态没有很好地建立,并且已经表明受抑制的RNR可能作为比活性复合物更高级的寡聚体存在。与基于机制的抑制剂和化疗药物吉西他滨(2 ',2'-二氟-2 '-脱氧胞苷)二磷酸一起孵育,已显示产生稳定的人和大肠杆菌的抑制复合物。coli RNR。本文对E.大肠杆菌和人类RNR使用X射线晶体学和小角X射线散射(SAXS)。目的1:确定人和大肠杆菌的四级结构. coliRNR的溶液中的SAXS。小角X射线衍射结构可以用来验证对接模型和未来的RNR复合物的晶体结构。提出的解决方案SAXS研究将提供深入了解如何E。大肠杆菌和人RNR可以响应于抑制剂形成不同的寡聚物种类,更重要的是,四级结构如何调节Ia类RNR的总体活性。目的2:确定吉西他滨抑制人RNR的晶体结构。吉西他滨结合的人RNR复合物的晶体结构将使我们能够确定这种药物如何修饰活性位点并破坏催化必需的自由基转移。这种结构还将使我们能够首次观察亚基之间的结合相互作用,并为靶向这种酶的化疗药物的未来设计提供见解。
公共卫生相关性:核糖核苷酸还原酶是一种在所有生物体中发现的蛋白质,是吉西他滨等抗癌药物的重要靶点。然而,与许多其他作为药物靶点的蛋白质不同,这种蛋白质的完整结构从未得到解决。通过研究这种蛋白质的结构,我们将更多地了解目前正在使用的癌症药物,并有助于未来的药物设计工作。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nozomi Ando其他文献
Nozomi Ando的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nozomi Ando', 18)}}的其他基金
NE-CAT: A Resource for Advanced Macromolecular Crystallography
NE-CAT:高级高分子晶体学资源
- 批准号:
10505648 - 财政年份:2018
- 资助金额:
$ 5.13万 - 项目类别:
Protein Allostery and Catalysis Beyond Bragg Diffraction
布拉格衍射之外的蛋白质变构和催化
- 批准号:
10677766 - 财政年份:2017
- 资助金额:
$ 5.13万 - 项目类别:
Protein Allostery and Catalysis Beyond Bragg Diffraction
布拉格衍射之外的蛋白质变构和催化
- 批准号:
10406516 - 财政年份:2017
- 资助金额:
$ 5.13万 - 项目类别:
Protein Allostery and Catalysis Beyond Bragg Diffraction
布拉格衍射之外的蛋白质变构和催化
- 批准号:
10806507 - 财政年份:2017
- 资助金额:
$ 5.13万 - 项目类别:
Protein Allostery and Catalysis Beyond Bragg Diffraction
布拉格衍射之外的蛋白质变构和催化
- 批准号:
10250499 - 财政年份:2017
- 资助金额:
$ 5.13万 - 项目类别:
Protein Allostery and Catalysis Beyond Bragg Diffraction
布拉格衍射之外的蛋白质变构和催化
- 批准号:
10798624 - 财政年份:2017
- 资助金额:
$ 5.13万 - 项目类别:
Structural Characterizations of Transient and Heterogeneous Protein Complexes
瞬时和异质蛋白质复合物的结构表征
- 批准号:
8417652 - 财政年份:2012
- 资助金额:
$ 5.13万 - 项目类别:
Structural Characterizations of Transient and Heterogeneous Protein Complexes
瞬时和异质蛋白质复合物的结构表征
- 批准号:
8895472 - 财政年份:2012
- 资助金额:
$ 5.13万 - 项目类别:
Structural Characterizations of Transient and Heterogeneous Protein Complexes
瞬时和异质蛋白质复合物的结构表征
- 批准号:
8225883 - 财政年份:2012
- 资助金额:
$ 5.13万 - 项目类别:
Structural Studies of Ribonucleotide Reductase Complexes
核糖核苷酸还原酶复合物的结构研究
- 批准号:
7806713 - 财政年份:2010
- 资助金额:
$ 5.13万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 5.13万 - 项目类别:
Continuing Grant